A promising weapon against measles
Researchers at LJI and Columbia University uncover exactly how a neutralizing antibody blocks measles virus infection
LJI strengthens ties between U.S. and Mexican scientists
“We’re glad to continue our support for this cross-border partnership and expand our work with young scientists and research leaders just across the border.”
Delivering better vaccines
LJI scientists share their visions for more effective, longer-lasting vaccines
Even as SARS-CoV-2 mutates, some human antibodies fight back
A 'cocktail' of human antibodies shows promise in fighting severe SARS-CoV-2 infections
We’ve learned a lot from lymphocytic choriomeningitis virus—now the time has come to fight it
LJI scientists share high-resolution view of the lymphocytic choriomeningitis virus (LCMV) glycoprotein together with a neutralizing antibody
Durable SARS-CoV-2 antibodies bind to two viral targets at once
A new study led by scientists at La Jolla Institute for Immunology (LJI) shows how ideal antibodies against SARS-CoV-2 hit their marks.
Rethinking the rabies vaccine
LA JOLLA—Rabies virus kills a shocking 59,000 people each year, many of them children. Some victims, especially kids, don’t realize
Unseen science
Dawid Zyla, Ph.D., is an immunologist and a skilled photographer. He shares a stunning look at the technical marvels behind biomedical research.
Promising antibody cocktail takes on Ebola virus—and its deadly cousin
LA JOLLA, CA—Researchers at La Jolla Institute for Immunology (LJI) are designing better therapies for treating Ebola virus and its
From Alpha to Epsilon: Consortium study illuminates surfaces of Spike most resistant to antibody escape
LJI-led Coronavirus Immunotherapeutic Consortium identifies antibody 'communities' with power to stop SARS-CoV-2 variants
COVID-19 research—a year later
5 takeaways from February's "Live from the Lab" webinar
Outbreak Alert: Coronavirus
Most coronaviruses usually cause the common cold, but, as happened with the SARS virus in 2003 and the MERS virus